The organ transplanted patient - immunological concepts and immunosuppression by Klintmalm, GBG et al.
A Vademecum Book 
R.G. LANDES COMPANY 
AUSTIN. GEORGETOWN 
1'.0. Box 4H58 
Austin, TX 78765 
Copyright © 1991 
RG. Landes Company 
All rights rescrV(.'<i. 
I'rinted in the U.s.A. 
ISBN 1-879702-06-1 
This book was published 
under an edllcational grant provided by 
ORrHO BIOTECH. 
The publisher and Editor 
gratefllllyackl1o'lvledge 
their generolls support. 
St,lteJl1enh and opinions expressed in this volume are those 
III thl' authors. Drug dnsesand treatment protocols reflect the ex peri-
ence 01 the contributors ilt the time of publication and are subject to 
change. Neither the publisher nor Editor guarantee, warrant or en-
dor~lD products or practices discussed in this manual. 
HANDBOOK of 
TRANSPLANTATION 
MANAGEMENT 
Leonard Makowka, M.D., Ph.D. 
CDirdector, Kaepart~ent of Surgery and Transplantation Services 
e ars-Smal Medical Center, Los Angeles 
Professor of Surgery 
University of California-Los Angeles 
A V qdernecum Book 
R.G. Landes Company 
Austin. Georgetown 
72 ~mmunolog;Cnf Concepts alld Immunosuppressiollll 
The Organ 
Transplanted 
Patient---
Immunological 
Concepts and 
CHAPTER THREE 3 
Immunosuppression 
Goran B.G. Klintmalm 
Bo S. Husberg 
Thomas E. Starzl 
I. The Rejection Process 
II. Modulation of the Immune Response 
III. Maintenance Immunosuppressive Therapy 
IV. Rejection Therapy 
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IlItrocillClioll. The first unsuccessful attempt to transplant a human 
kidney was done in 1936 by the Russian surgeon Yu. Yu. Voronoy.71 In the 
early 1950s several other attempts were made but without long term suc-
cess. ~fK!bK IK. DvK~T Finally in 1954 the first successful human kidney transplant 
was performed with an identical twin donof'*' confirming that if the problem 
of immunosuppression could be overcome, renal transplantation was a cure 
for uremia. Total body irradiation was employed as a means of immunosup-
pressionO~K 42 but quickly abandoned as a consequence of its prohibitive 
morbidity and mortality. 
----_ ... __ ._._ ....... - --... -. 
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Two basic concepts related to organ transplantation of today were not 
obvious when clinical organ transplantation started in the early I 960s. Based 
on available data from animal experiments many immunologists advised 
against clinical organ transplantation at that time. They were: 
I. It is possible to suppress the immune response to a foreign organ 
without suppressing immune responses to microorganisms to an unaccept-
able degree. 
2. It is possible to reverse a transplant directed immune response that has 
already reached the point of production of effector cells and antibodies. 
In order to understand how these goals have been attained. a basic 
knowledge about the human immune system is mandatory. Obviously it is 
necessary to interfere with the capacity to evoke immune responses in a 
selective way and to develop methods to diagnose the presence of such 
responses. Still, in a situation when a life threatening infection is present. it 
is often necessary to stop transplant directed immunosuppressive measures to 
save a patient's life. However, often a catabolic state of such a degree is then 
present that the discontinuation of the immunosuppressive treatment does not 
result in immediate rejection of the transplant. 
The human immune response system is described in detail in every 
textbook of basic immunology. (See Glossary at the end of this chapter.) The 
transplant antigens belonging to the MHC (Major Histocompatibility Com-
plex) are the molecules on the cells of the transplanted organ that challenge 
the immune defense system of the host. The antigens are mainly present on 
lymphoid cells that leave the graft by the transplant vein or by lymph 
channels. MHC antigenic structures on the parenchymal and endothelial cells 
of the transplanted organ are the targets of the resulting (or any preexisting) 
immune response. 
I. The Rejection Process. 
The transplant antigens that reach the host are first phagocytosed into 
macrophages. After processing they are presented to antigen sensiti ve T and 
B cells with the help of a messenger substance (lymphokine) called inter-
leukin-I (lL-I). A burst of mitotic activity ensues in the activated cells and. 
after maturation. a number of cells able to recognize and destroy cells carrying 
the challenging antigens are produced. The system is outlined in Fig. 1. 
Cytotoxic lymphocytes (sometimes referred to as "killer cells") are produced 
as a result of the T cell (thymus dependent) response to the antigen, and a 
number of plasma cells capable of producing antibodies specific to the 
challenging antigen is generated as a consequence of the B cell (bursa 
dependent) response. The resulting attacks on the target cells are initiated by 
these cells and antibodies with specificity against the foreign cell surface 
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antigens. However. once the cells begin to suffer they leak intracellular 
components that attract other host lymphoid cells by nonspecific chemotaxis. 
This population of "natural killer" (NK) cells participates in the attack 
without having a preexisting antigen directed specificity. Further damage 
attracting more cells occurs. and soon the NK cells vastly outnumber the 
initiating "specific" cells. Thus the system hasa built-in fast acting amplifier 
once a reaction is initiated. 
The antibodies produced belong to different immunoglobulin subclasses 
called IgM. IgG. IgA. IgD and IgE. IgM antibodies are the first to be produced 
after an antigenic chalJenge. They are highly agglutinating and cytotoxic 
together with complement and have the highest molecular weight among the 
subclasses. Later in the immune response. IgG antibodies are produced. and 
they then decrease the IgM antibody production by feedback inhibition. IgG 
antibodies can be cytotoxic with complement orcan block (protect) the target 
cell surface antigenic structures. IgA. IgD and IgE antibodies are not thought 
to have a primary role in transplant rejection processes. The working units of 
all antibodies are made up of two identical light (lambda or kappa type) and 
two heavy protein chains. A structurally different kind of heavy chain exists 
for each ofthe five classes of immunoglobulin. Antibody molecules can also 
be fractionated in such a way that the complement binding (Fc) portions, but 
not the antigen binding (Fab) parts. are lost. Such antibody fragments retain 
their ability to bind (and block) the target antigens. but cannot initiate the 
target cell lysis. As a general rule. although with numerous exceptions, the 
antibody mediated branch of the immune response is of major importance in 
immune responses against infectious agents (particularly bacteria) while the 
cell mediated branch is of primary interest during rejection processes. 
Two other cell types are of importance for the development of the 
immune response to a foreign antigen (Fig. I). The "helper/inducer" cell and 
the "suppressor/cytotoxic" cell both belong to the T cell family and influence 
both the T cell and B cell mediated arms of the immune response. The helper/ 
inducer cells send a signal to the precursors of the cytotoxic T cells and plasma 
cells in order to allow them to mature. This signal is conveyed by the 
Iymphokine "interleukin-2" (lL-2). The suppressor/cytotoxic cells are 
thought to interact with the helper/inducer cells and can prevent the matura-
tion of both Band T cells into effector cells. However they cannot be 
differentiated with certainty from the cytotoxic T cell popUlation by cell 
surface markers. Nor has it been possible to identify a gene for the develop-
ment of specific suppressor cell activity with DNA clone techniques. Their 
"suppressive" effect can be studied with ease in vitro but not in vivo, and 
suppressor cells from in vitro experiments can even help nude mice to mount 
an in vivo immunoresponse.43 These facts have led several reputable immu-
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llologists to doubt that there is a structural difference between suppressor and 
cytotoxic T cells. 16 This is the reason behind the somewhat contradictory 
name "suppressorlcytotoxic" cell. 
Clinically, hyperacute, acute and chronic rejection processes can be 
differentiated from each other. The hyperacute rejection may occur after 
kidney, pancreas, heart and probably also liver transplantation as a conse-
qucncc of a reaction between preformed complement binding cytotoxic 
antibodies in the recipient and antigenic structures (mainly situated on the 
vascular endothelium) in the transplant. The organ is destroyed within 
minutes. Acute rejection is mainly mediated by killer cells generated in the 
grafted patient 5 to 15 days after transplantation. Chronic rejection is a slow 
process with few clinical symptoms. It gradually diminishes the transplant 
function and is microscopically recognized by a pattern offibrosis, parenchy-
mal cell death and intimal thickening. Both cellular and antibody mediated 
imlllune responses playa role in chronic rejection. Of the three types of 
rejection. only the second can be treated with a good long term outcome. 
11. Modulation of the Immune Response. 
Tools that are capable of dealing with subgroups of cells involved in an 
immune response are obviously highly desirable. The first prerequisite for 
~lfch tools is that markers enabling us to identify the different subsets of cells 
havc to be at hand. Such markers are now available to some degree, and the 
dillcrent cells can thus be made into targets for manipulations ofthe immune 
rcsponses. The nomenclature involved in the surface markers has been far 
fro III unified. and attempts are being made to create a logical and universally 
accepted systcm. Thc nomenclature that is used at the present time divides the 
ditll'rcnt T cell ,1Ihsets into "clusters of differentiation" (CD). The CD 
numbcrs givcn to different T lymphoid cells are shown in Fig. I. An 
ilnalogous B cell subsct nomenclature is under development. 
The s ystcm now outl i ned can be influenced so as to accept a foreign organ 
transplant in several ways. 
I. Thc immune system of an organ transplant recipient can be taught to 
consider the foreign transplant antigens as "self' creating a "tolerance". 
2. A c1a~s of antibodies capable of blocking the transplant antigens rather 
than attacking them can be produced as the result of the antigenic challenge 
("cnhanccment" ). 
3. Donor selection can be made to ensure that the antigenic determinants 
~pccific to thc cells of a given individual donating an organ are as similar as 
pos~iolc to the corresponding antigens of the person who receives the 
tran,plant. 
4. Thc mitotic activity eventually resulting in the production ofimmuno-
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co~petenteffectorcells can be blocked by antimitotic agents, e.g .. by azathi-
opnne [Imuranl. 
. 5. The effector cells resulting from an antigenic stimulus can be removed 
killed or defunctionalized, e.g., by glucocorticoid. . 
. 6. The IL-2 conveyed message from the helper/inducer cell to the 
activated T c~lf can be blocked. This results in a suppressive effect directed 
at the cytotoxIc T cells, e.g., by cyclosporine A (Cy A) and FK506 treatment. 
. 7. :rhe surface.markers t~at are specific to cells providing a key function 
~n th~ fmmunolo~lcalK rea~tlln against the transplant can be destroyed or 
ma~tlv~ted by antibodies directed against these markers, e.g., by monoclonal 
antibodies. 
. Ad 1 and 2: The concepts of tolerance and enhancement are of great 
~nterest a~d can be made to work in an impressive way in standardized and 
mbred am mal models. However a treatment failure can result in sensitization 
and so f~r no reproducible ~uman treatment strategies have been presented. 
At one lime blood transfUSIOns pretransplantation were thought to induce an 
en~ancement-type host unresponsiveness following organ transplantation. 50 
ThiS effect a~pears not to exist in cyclosporine/steroid treated patients." 
Ad 3: ThiS represents the well-known and thoroughly studied concept of 
tiss.ue t~Dpi~gK Its overall importance in the age of CyA and monoclonal 
antibodies IS so~e~hat controversial33. 49 but, as it still governs the clinical 
trans?l.ant practice m more centers, it is important for transplant surgeons and 
phYSICians to be familiar with the system. 
Major Histocompatibility Complex (MHC) antigens are known in all 
~ertebrate species studies. The MHC antigenic structures are often divided 
mto two classes called I and II. The antigens of the former class are present 
on nearl~ all nucleated cells, while the antigens of the latter class predomi-
nantly eXist on the cells that present the transplant antigens to the host immune 
sys~emI na,:"ely: monocytes, macrophages and B lymphocytes. The class I 
ant~gens ~nmanly create a cellular immune response while class II antigens 
mamly stlf~1rlate the plasma cell antibody immune sequence. Class I mole-
cules consist of two parts, one larger polypeptide chain and a smaller chain 
called B2-microglobulin. Class II molecules consist of two polypeptide chains ?f about the same size. Both class I and class II molecules resemble 
Immunoglobulins. The human MHC system is called HLA (Huma! L -
. 1 "eu 
cocy!e Antigen). All the genes controlling class I and II antigens are situated 
on ~ffferent loci on chromosome 6 (except those controlling B2-mieroglo-
buhn). Every human being has two alleles on each of the A Band C I .' 
. ' . OCI 
governmg the c~ass I ant~gensK These genes constitute the basis for serological 
HL.A-A. and ~ tissue typmg. Also on chromosome six are the DP, DQ and DR 
lOCI which direct the production of class II antigens and constitute the oasis 
7H 
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for clinical DR typing. In clinical everyday practice the A. B and DR loci are 
lIsed to define a patient's tissue type. 
The different human antigens belonging to the HLA-A. B and DR 
systems have been identified by the collection of a vast number of sera from 
multiparous women and multitransfused m.en a?d wo~enK The perso.ns of 
interest are those that have developed antibodies agamst MHC antigens 
present on white blood cells and other nucleated cells. After absorptions and 
cross testing between panels of antisera and lymphocytes from blood donors. 
it has been possible to identify antisera that are monospecific. that is. directed 
against one HLA antigen. Today more than 50 HLA A and B. as w:1l as ~t least 
13 DR antigens. are known. Each individual should have three fdenu~able 
antigens on each chromosome for a total of 3-6 HLA A-B and DR designa-
tions depending on whether homozygosity on the loci exist or not. An 
individual's HLA pattern can be determined by the addition ofaliquots of 
viable lymphocytes and complement to trays with multiple micro wells each 
containing a specific HLA anti-serum. The detection of the pattern is based 
on the complement dependent cytotoxic reaction which results in a number 
of wells containing dead cells. The total reactivity then determines a person' s 
tissue type. 
As all human A. B. C. DR. DP and DQ genes are linked on the same 
chromosome, a simple "Mendelian" heritage pattern is present among sib-
lings for each group ofhaplotypes. Twenty-five percent of siblings are.H.LA 
identical to each other. Such individuals constitute excellent organ-recIpient 
pairs. However since such transplant recipients need transplant protective 
immunosuppression it is obvious that some genes not residing on chromo-
some six also control non-HLA histocompatibility antigens. 
Although the degree of his to incompatibility does not have major influ-
ence on the results of organ transplantation with cyclosporine A treatment in 
many centers, two recent discoveries have made it clear that MHC antigens 
are of major physiological and pathophysiological importance. 
First, there are clearly associations between certain HLA types and 
specific diseasesK~T The correlation is most obvious between HLA type B 27 
and .tnkylosing spondylitis, but several other associations have been discov-
ered. They mainly involve diseases where autoimmune processes have been 
considered. That is, for instance, type I diabetes mellitus, rheumatoid arthritis. 
Reiters disease and SLE. 
Second, it has been shown in mice and more recently in man that virtually 
all T cell mediated immune reactions are regulated by MHC gene products (so 
called ·'MHC restriction").56Thus an immunocompetent cell, with its speci-
ficity directed against a certain microorganism, can only attack the foreign 
antigens if those are in close contact with Class I MHC structures of the same 
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kind as the attacking cell. This means that the combination of "self MHC + 
foreign antigen" is recognized. The validity of the principle can be demon-
strated in vitro where virus particles having infected a monolayer of human 
cells only can be attacked by lymphoid cells sensitized to the appropriate viral 
antigens ifthe lymphoid and monolayer cells have class I MHC determinants 
in common. 
Pretransplant crossmatch. The pretransplant crossmatch is of undis-
puted and paramount importance in the efforts to reduce the incidence of 
hyperacute rejection after kidney and heart transplantation. It is ofless signifi-
cance when liver transplantation is performed. The crossmatch is done with 
fresh serum from the intended recipient which is mixed with complement and 
donor lymphoid cells isolated from blood. spleen or lymph nodes. In multi-
transfused patients peripheral blood might not contain enough representative 
lymphoid cells. Also ifthe donor patient has received steroid treatment, this 
induces lymphocytopenia in peripheral blood. Splenic cell preparations are 
often contaminated by neutrophils and macrophages to the extent as to make 
the reading of any reactions more difficult. A relatively pure preparation of 
Band T cells can be prepared from lymph nodes. 
f~ a direct cytotoxic effect is recorded. usually by a vital staining 
techmque, the crossmatch is "positive" due to the presence of antibodies that 
are capable of destroying the transplant. Such antibodies in the prospecti ve 
recipient are indicative of a high likelihood of a hyperacute antibody-
mediated rejection within minutes after revascularization. The crossmatch 
should be carried out with recipient serum added to different subclasses of the 
donor lymphoid cell population and at different temperatures. Thus recipient 
serum is usually tested against donor B cells, T cells and monocytes. Band 
T cell crossmatches are carried out at room temperature and at 30"C. T cell 
crossmatch activity is also checked at +4"C. If a T cell cytotoxic reaction takes 
pl~ce at any ofthese temperatures, the crossmatch is. reported as "positive". 
Ills generally accepted that a positive Tcell crossmatch predicts a substantial 
risk for a hyperacute rejection at least after kidney. heart and pancreas 
transplantation. An isolated positive B cell crossmatch has been reported by 
some to predict a favorable outcome of the planned transplantation. Others 
have found that preexisting B cell mediated immunity predicts a transplant 
course with frequent rejections. The monocytes are thought to share antigens 
with endothelial cells. A positive monocyte crossmatch has been reported to 
predict a risk for an acute antibody mediated atta~k directed at the graft 
vasculature. A full crossmatch test takes about six hours to perform. 
The number ofHLA specificities among the preexisting antibodies can 
be tested against a panel of lymphocytes from blood donors at routine 
intervals before transplantation. Apanel reactive antibody ( PRA) percentage 
------_._---------------------,-
Hll 
figure is thus established. A low number predicts a gOO? cha?ce to ~btai~ a 
ncgati ve crossmatch when an organ is offered. The uremic patients with high 
PRA percentages will thus have to wait longer for their kidneys as comp.ared 
to those with loll' PRAs. In all kidney procurement areas, sera from patients 
with high PRA 's arc collected on "high reactor trays". Lymphoid cells from 
organ donors and complement are added to these trays bef~reK kidney 
recipients arc selected. A negative reaction, i.e., lack of donor cell kllltng, then 
constitutes priority to one of the kidneys at hand. . 
Blood groups. Blood group identical transplantation is sought even If 
organs can be transplanted according to the standard compatibility rules for 
red cell transfusion. If an uremic patient with a high PRA percentage has a 
negat i ve crossmatch with a blood group nonidentical but compati~le ~idneyI 
the patient will be offered this organ. Obviously in the long-ru~I thIS "':'111 have 
the conse4uence that a pool of uremic nontransplanted 0 patlent~ Will accu-
mulate. At the same time, all AB kidneys cannot be placed. The use of A2 
kidneys in () patients has been proposed as a partial solution to this problem. 
Persons of blood type A can be subdivided into AI (approximately 80%), and 
A, (approximately 20Ck). The A2 antigen is considered to be so ,":eak as to 
allow a blood type incompatible transplantation. A substantial patient ~~te­
rial showing promising results was published,9 but after further chmcal 
studies the procedure is generally felt to create an increased risk for acute and 
hyperacute rejection processes. In liver transplantation, blood type nonid~n­
tical and even incompatible combinations are possible in emergency sllu-
at ions. Hyperacute rejections generally do not occur; however, a price in 
decreased statistical graft survival has to be paid. 
Ad 4-7: The mode of action of most inununosuppressive agents used 
today falls under these categories. They, therefore, represent the current 
~tandard immunosuppressive therapy. 
The major immunosuppressive agents currently employed by us for long 
term maintenance therapy in solid organ transplantation are corticosteroids, 
azathioprine, cyclosporine, cyclophosphamide and the new (still experimen-
tal) drugs FK506 and RS6l443. Corticosteroids. OKT3 antibodies and ALGI 
A TG are the most commonly used agents in the therapy of rejection proc-
esses. The new drugs FK506 and RS61443 may also have a role in rejection 
treatment. 
III. Maintenance Immunosuppressive Therapy. 
A. Corticosteroids. Adrenocortical steroids were the first pharmacol-
ogic agents tried for immunosuppression on rodents in the early 1950s.7.44 
Despite extensive investigation, the precise mechanism ofthe immunosup-
pre~siy"e effects of corticosteroids has not yet been elucidated.l.15.19.2o.66 What 
The Handbook o/Transplantation Management 81 
is known is that these compounds penetrate lymphocyte cellular membranes. 
Corticosteroids are believed to act intracellularly to reduce production of both 
interleukin-I from antigen presenting cells and interleukin-2 from activated 
lymphocytes. 
There are four major corticosteroid compounds which are used clini-
cally: hydrocortisone, prednisone, prednisolone and methylprednisolone 
(see Table I). The side effects of each ofthese steroid compounds are related 
to the dose and duration of therapy. Hydrocortisone is available only for 
intravenous administration. In addition this compound possesses significant 
mineralocorticoid activity which must be taken into consideration in clinical 
immunosuppressive regimens. 
Methylprednisolone, prednisolone and prednisone are the three steroid 
compounds used most frequently for both the prophylaxis and treatment of 
graft rejection. These drugs have been selected because they possess a high 
antiinflammatory potency in conjunction with low mineralocorticoid acti v-
ity.J,66 Methylprednisolone, which has the least mineralocorticoid effect. is 
available for both oral and intravenous administration; however the high cost 
of the oral form of this steroid has limited its utility for chronic patient 
immunosuppression though it is used extensively in most standard early post-
operative immunosuppressive regimens. 
Prednisone is rapidly absorbed from the gastrointestinal tract; however 
hepatic metabolism to prednisolone is required for biologic activity. 1 The 
resultant bioavailability of administered prednisone is approximately 807c as 
a consequence of this required metabolism. In the case of methylpredniso-
lone, the intravenous form possesses a succinate moiety which must be 
hydrolyzed by the liver for steroid acti vity. In addition this compound has 
multiple active metabolites which prolong its biologic half-life. As the oral 
and intravenous dosages of prednisolone are equivalent and no hepatic 
metabolism is required for steroid activity. wepreferthis steroid agent to both 
prednisone and methylprednisolone. 
Steroid compounds are primarily inactivated by hepatic metabolism 
through reduction and conjugation and are then excreted in the urine.1..1 Thus 
changes in the status of the patient's hepatic function may markedly influence 
the inactivation of steroid drugs (and in those cases where hepatic metabolism 
is required for activity, can alter their bioavailability). In patients with 
cirrhosis the half-life of steroid compounds may even be doubledK~o A similar 
alteration in steroid metabolism is probably seen during acute hepatic 
allograft rejection. This should be considered in planning a standardized 
therapeutic postoperative steroid regimen. 
Many commonly employed antiepileptics, including phenytoin and 
phenobarbital, as well as other clinically important drugs, such as rifampin, 
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Q) act to induce the hepatic P450enzyme system. This dramatically shortens the 
c biologic half-life of steroid compounds in patients taking these medications2O 
~ ~ iii resulting in a decreased allograft survival72 unless adequate additional steroid ~ '2 c is given to compensate for this increased turnover. We have found that a 50% ~ c::: c:::-g 'E increase in the standard protocol steroid dose to patients receiving predniso-
~ 'E 'E Ci 0 ... 
~ 0 00 0 .r::. lone and azathioprine successfully ameliorates the problems with increased 0> <a~ (\j to incidence of rejection. 
The majority of immunosuppressive protocols begin with a high-dose 
burst of steroid therapy followed by a stepwise dose reduction. When not used 
<Ii in conjunction with cyclosporine, prednisolone is started at 150-200 mg daily I~ "0 >-£.0 X ~ en and tapered slowly to reach a dosage of approximately 30 mg daily at one u ,- e I'tl 8 "Om 0. . - CD 
~t CD c 0. I/) i!D;~ month and 10-20 mg daily at one year. Cyclosporine has been referred to as ~~ 0. ~:~ '0 ~ 8 as a steroid sparing drug allowing a more rapid taperofthe steroid dosage. This 
,- 0 .8 .!a ! 1iF~p 0>- as c as :l ... CD may be due to the stronger immunosuppressive effects ofCy A in comparison 
.2 ~ -"0 E.E E o OJ CD OJ I/) to azathioprine, or a synergism in their action, but may also reflect an ~- c::: E ... E Q) ... CD .0 ,- :=0. 
- OJ > >-E ~b as>:;:: interference between CyA and steroid metaboiism.J6. s2 2! (ij- C:E c:= U .- as c: _ c::: :l ... 8 ~ CD Our present prednisolone protocol when used in combination with Cy A as I'tl CD 0 ...: 0.Q) OJ 15 ,2 i- ..... CD -otU :l--E Q) ~ .- ~ g!K~ :a·S I/) >..9- is summarized in Table 2. In triple drug regimes including azathioprine. we E E §II~ ~r-; nFKn~ employ even lower steroid doses (Table 3). Daily doses ofless than 10 mg are (5 ;?!i .r::.=:l E ,- U EasoS l-oE _enl'tl 
usually not used in the adult patient. In the pediatric recipient, efforts are often 
made to convert to alternate day therapy in an effort to minimize the side 
effects, This should not be attempted until the long term maintenance dose has 
0> 
been reached and only then with considerable caution. 
c 
- OJ 
0> E Cl Cl I. Side Effects. i. Infections. Incidenceis directly related to the steroid 
0 c: II) E r-- E E dose. A time correlation is seen with rejection therapy. The patients are K~ 
.l!18 0 Lti II) ~ 
E ~ C\I sensitive not only to normal pathogens but also to opportunistic infections 
I'tl :3 0. Jr such as Pneumocystis carinii, Listeria monocytogenes, cytomegalovirus. (/) c herpes simplex virus. herpes zoster, Candidaalbicans, Aspergillus, Nocardia I'tl 
~ asteroides and reactivation of Mycobacterium tuberculosis. Thus do not 
c::: 
order rejection therapy lightly. I'tl iD e ~ iD CD ii. Poor wound healing. Staples and sutures should be left undisturhed for I: 1:: "0 0 1:: 0 8 Q) 
,£; III 0 I/) E three weeks. E U .ll! ~ :l "0 ~ OJ ~ '0 (ij '0 iii. Muscle weakness. Seen particularly in the knees. It manifests primar-(/) en Q 0 en 
:::> ~ ily after rejection therapy. (/) 
"0 ~ iv. Osteonecrosis. Particularly in hips and knees, itcan effect other joints, (5 f-;: 
often bilaterally. It has no clear-cut dose relationship. The symptom is Q5 OJ Ui I: localized pain. Only symptomatic therapy is available. Joint replacement may 0 0-
U -> 
't: OJ OJ 0- be required. I: I/) ... 0 E 0 CD ·2.E v. Cataract. It occurs in less than 10% of patients. Seen as a posterior pool () OJ c ~ (/) I: 0 "OQ) 't: 0 '0 !iij lenticular cataract. It results in variable degree of impaired vision; lOOk to 0 0 Vl I/) 
.9-1: W ~ t::: U 'c '2 20% of affected patients need cataract surgery. 0 >- .-
.J OJ 
-c 15 "0 oS 8 co c: ! ! Q) :l ~ OJ >- :E.!!!. I- <-' I a... a.. 
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I'i, Steroid diabetes. The incidence increases with patient age and with a 
hereditary trait for diabetes mellitus.24 Etiology is obscure. but increased insu-
lin resi stance, increased gl uconeogenesis and hyperglucagonemia may con-
trihuteK~D 
I'ii. ('1I.lhiligoid ilabilllS. It is more frequent in younger patients and is 
dose related. It usually improves when the daily dose is reduced to 20 mg/day 
or less. 
l'iii. GllStmilitestilia/. Pancreatitis, gastric and duodenal ulceration and 
colon perforations are uncommon but feared complications. They are more 
commonly seen in rejection treated patients. Symptoms ofGI perforations are 
vague. Accurate and early diagnosis requires a high level of suspicion. Signs 
of peritonitis are uncommon; usually there isonly localized tenderness, even 
in cases with perforation. If not diagnosed and treated early, perforations in 
tran~plant patients carry a grave mortality. Preoperative evaluation of the 
prmpecti ve transplant recipient should include a search for active peptic ulcer 
disease and diverticulosis coli. 
ix. flrpertellsio/l. Steroids may contribute to hypertension because of 
t hc i r III i ncra I ocort icoid effect. Other primary etiologies should be considered, 
i.e., renal artery stenosis, chronic renal allograft rejection, renin production 
from native kidneys and cyc\osporine A toxicity. 
x. Ohesitr. Steroids increase appetite. and with normalization of the 
paticnt's diet excessive weight gain is often seen beginning one to two months 
after transplantation. Patients require dietary counseling during their trans-
plant hospitalization to avoid this complication. 
xi. Centralnen'olls system. Insomnia and mild euphoria or depression are 
common. Psychosis is rare. Psychotic reactions usually respond well to 
haloperidol (Haldol) administration. Chlorpromazine (Thorazine) is hepato-
toxic and should be avoided where possible. It should be remembered that 
in,omnia is most commonly caused by beta blockers. 
xii. (J/,{/lI'th retardation. A serious problem in the pediatric transplant 
population. Altcrnate day steroid administration may be of benefit and 
warrants consideration in long term immunosuppressive regimens for the 
pcdiatric recipient. 
R. Azathioprine. In 1961 azathioprine, the imidazole derivative of 6-
llIt:rcaptopurinc. was studied on dogs ll and subsequently cIinicaIly.40 The 
utility of this drug as a single immunosuppressive agent was severely limited 
by its profound systemic toxicity at high dosages. Ultimately in Denver in 
1962 it was dcmonstrated that, by using maintenance corticosteroids with 
alathioprinc and treating rejections with high dose corticosteroids, rejection 
could be reversed and a state of graft acceptance established.bJ By 1964 this 
"douhle drug" immunosuppressive regimen had become the gold standard. 
The Handbook a/Transplantation MJznagement 87 
The co~bination of azathioprine and corticosteroids is usually referred to as 
conventIonal ther~pyI with ~r without the addition of antilymphocytic62 or 
lymph~yte ~epletmg ~echmquesK 2J Azathioprine is metabolized by the liver 
to the bllloglc~lly aC~lve compound 6-thioinosinic acid. An important im-
munosuppressIve actIon of this drug is the inhibition of cellular DNA and 
~kA synthesis. Azathioprine effects both the humoral and cell mediated 
fmmu~e respo~ses; however, only partial systemic immunosuppression is ac-
complished WIth the do.sages generally utilized in clinical practice. 
. The enzy~e xanthme oxidase is involved in the metabolism of azathi-
opn~eK ~~cordmglyI concomitant therapy with allopurinol. a xanthine oxi-
dase mhlbltor,. can be hazardous as a consequence of noteworthy increases in 
bo~h the ~~gmtude of systemic immunosuppression and the drug's hematol-
ogl~ toxIcIty. If therapy with both of these agents is mandatory. the azathi-
opnne dos~ sh?uld .be red~ced to 25-30% of that customarily used. I. 2 
Aza!hlOpnne IS aVaIlable in both intravenous and oral forms. Its 
~etabol~t~s ~~e excreted in the urine. Therapy is started prior to transplanta-
tion and IS 1~ltlated at 2-3 mg/kg/day. Oral and intravenous doses are approxi-
~ately eqUIvalent. After oral administration, a maximum blood level effect 
IS seen after 1-2 hours. Azathioprine should be given daily as a single dose not 
to exceed 2()() mg/day. 
The dosage of this agent should be adjusted in accordance with the 
patient's t?tal white blood cell count. The dose is adjusted down when rapid 
decreases 10 WBC count are seen or when the WBC count is less than 5000/ 
mI. The dose should be completely withheld or reduced to 25mg/d with WBC 
counts of less than 3000/ml. 
1. pid~ EIfects. i. eem~tologicK Bone marrow suppression is significant. 
ieuk~pema IS al",Jost umversally seen and often prevents the use of an 
effectIve thera~eutlc dose. !hr~mbocytopenia may also mandate dose adjust-
ment or ce.ssatlon of azathlOpnne therapy. Anemia is an uncommon occur-
rence. An fm~ortant consideration is that viral infection, most notably with 
cytomegalOVIrus, can also cause leukopenia. 
ii. eepa~icK Azathioprine is potentially hepatotoxic. This is seen clini-
cally a~ an mcrease .in bilirubin and serum transaminases. Before cy-
cl?sponne A was aVaIlable such patients were switched to cyclophospha-
mIde. 
ii~K Other. ~robKlematic hair loss and skin fragili~y may improve after cx-
changmg azathlopnne for some other immunosuppressant. 
C. Cy~losporine A .. f~ 1978 in Cambridge a new immunosuppressi ve 
agent w~s mtroduced. chmc.ally for transplantationY CyA is a lipophilic 
metabohte f~om the SOIl ~ung~ Tolypocladium inflatum GAMS and Cylilldro-
carpum luC/dum Booth. It IS a cyclic endecapeptide containing a unique, 
HH 
, "d This amino acid is essential for immunosup-
pn;viollsly unkno~n ammo aCI " d tthe time ofits introduction it was 
pressive effect. It IS not myelotoxl~I an a tk own The clinical introduction 
T 'mmunosuppresslve agen n ' \ 
the most speci Ie I "d' h ther agents such as prednisone6, has 
of CyA parli<:ularly co~nbme wit ~ aft and patient survival after all 
I d' ' 'ficantlmprovement tn gr , 
resll te m SlgOi , 'd' t est in transplantation as a therapeutIc 
organ transplants, spurTIng a WI ertn er 
modality. " ,.\ th T cell immune response, in particular. inter-
Cy A alleelS Kpfll~Tan y r:vention ofinterleukin-2 production seems to 
\cllkin-2 productIOn. The p ,++' \' ossibly by binding between CyA 
include interference wIth the C~ plgn~K ~ I ed in Ca++ mediated activi-
d r toplasm'ltlC protem mvo v 
and calmo 1I m. a cy " k f' terleukin-2 production is the 
tics," The net effect from the bloc ag~ 0 tn db allogeneic cells. 
CI I' d Class II antigens expresse y rai I ure to react to ass an . . , . . . T lymphocytes. 
I d)f events leadmg to cytotOXIC t\1I1S preventing tle casca e (, . b d f m the proximal jejunum, and 
II d ' i 'tered Cy A IS absor e ro 
Ora y a mm s i 4 h The half-life varies widely between 
peakhloodlevelsareseenafter - o~~K b' availabilityoforalCyAisonly 
16 and 42 hours, averagmg 27 h?~rsI e I;e Thus when changing a patient 
34(1c (range 2()- 5OC';{-) of the a~mlKmsteredd~P ~ftheoral dose should be given. 
from oral to intraven.ous ~ledl~a~ylnI ~~fvK1 mplex, At least three metabolites, 
The drug' S ll1etabo\tsm IS hepatic an I,SCO I' lly active, The drug is 
MI M 17 and M2 I. are known to be Immuno oglc~ . A is not 
. I I' philic and the renal excretion is neghglble, 0.1 %, Cy 
extreme y IpO 
d' I ble ~IhK~T I' t' Ja yza '. 'k' t' and pharmacologic a mterac Ions 
Clinically Important phar~:c~ f;:;~ enzyme system in the liver is a 
afe c(lIll\l1,on. I nterference wit tel dh'lgh dose steroids increase the 
. f' traction Ketoconazo e an 
commonslteo me. ., d 'fam inreducetheCyAlevel.Other 
Cy A level. PhenytOIn. bar~lturatesKan nh thPe aminoglycosides. amphoter-
. I' l'I"ologIC agents sue as 
nephwtox IC P larn , '- , 'h' _sulphamethoxazole may 
icin B. melphalan.trimethopnmand tnmet opnm , h C A 
h . 't when used together Wit y. 
callse increased nep rotOXICI y . f d 'n the blood cells with only 30-
In whole blood 50?v o~th: ~yA f~ ~unun~Is C A's affinity for red blood 
,lOC! in plasma 90% 01 whIch IS protem bo Y. d' hole 
II , Th th CyA concentratIOn measure tn w 
cells varies with temperature. us e , Unlike whole blood 
blood is totally diffe.rent from that m~asured tn ;~~:~;~he plasma atthe time 
concentralion.CyAlsdependentont etemperat t'ons are performed in a 
, .. on ~T When plasma concen ra 1 
01 plasma separa.. . r ble as whole blood for the purpose of 
standardizcd fashIOn. thcy are as re la 
patient monitoring. . ' fC A concentration: ra-
Thrce techniqucscxist for the determmatlon 0 y I 'b d' high 
. 01 clonal or monoclona anti 0 les. 
dillimlllunoassay (RIA) ustng P Y 1 I I fluorescent polariza-
pressurc liquid chromatography (HPLC)orpo yc ona 
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tion immunoassay (FPIA). The polyclonal RIA is approximately similar to 
the RIA kit previously supplied by Sandoz. The polyclonal RIA has a high 
degree of cross-reactivity with CyA metabolites (up to 60%) whereas the 
monoclonal RIA and the HPLC measure only the parent compound A. The 
HPLC results are approximately 10% higher than those obtained by monoclo-
nal RIA. The FPIA technique is very sensitive and measures most of the 
metabolites, which can be problematic, During good liver function the 
proportion of the mother compound (HPLCO, monoclonal RIA) is 50-60% 
of the measured FPIA level. In poor liver function, this can go down to 10-
15%. When the liver function deteriorates. i.e., in liver transplants, the liver 
is less able to excrete the metabolites which accumulate. This gives an 
impression of too much Cy A resulting in a lowered Cy A dose and the level 
of mother compound, which is mainly responsible for the immunosuppres-
sive effect, becoming too low. triggering a rejection. We have seen this 
happen several times in patients monitored with the FPIA assay and conse-
quently advise against its use in patients with poor or deteriorating liver 
function, 
Standards for both the recommended dose and for the optimum therapeu-
tic levels ofCy A have been dramatically reduced since the introduction of this 
drug. This is primarily a consequence ofincreased understanding of the drug 
levels necessary in vivo and an increased awareness of the drug's chronic 
nephrotoxic side effect. The maximum clinical utility of cyclosporine is 
achieved by a successful admixture of scientific knowledge and clinical 
acumen. 
Important nuances in cyclosporine management include: 
a. Cyclosporine is always a nephrotoxic agent, even at minimal doses. 
b. One should never react to a single laboratory determination of cy-
closporine level. If the blood level suddenly increases without evidence of a 
change in renal function. repeat the assay; do not change the cyclosporine 
dose. The most sensitive laboratory value indicative of cyclosporine nephro-
toxicity is a rising BUN. Corresponding changes in serum creatinine occur 
but manifest more slowly. Once a long term maintenance Cy A dose has been 
established. only very rarely should the dose be increased as a response to a 
decrease in measured blood (or plasma) levels, The optimal therapeutic level 
for long term patient management has not been conclusively established. 
Again, the current trend has been to lower recommended maintenance Cy A 
levels. 
c. When dose changes are indicated. add or subtract 20% of the previous 
dose in 25 mg/dose steps, 
d. Because o/CyA 's long half-life, several days are required to achiel'i' 
steady state blood levels after any dose adjustment. Remember this and act 
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e. EI'ellthe best/aborlltories have a variation of ±lO% in their measured 
reslI/t\ /Ising RIA technique. 
(. lJlood lel'els IIl/Ht be drawnjust before the morning dose. For longterm 
management the patient can safely delay ingestion of the morning dose until 
the hlood work has been drawn on the day of an office/clinic outpatient visit. 
g. Remember the q{orementioned clinically important drug interactions. 
II. l1!e intrlll'enous dose is approximately one-third of the oral dose. 
f. Side Effects. i. Nephrotoxicity. Nephrotoxicity is seen in two forms, an 
acute reversihle form which is most likely caused by increased sympathetic 
nervous tone and a chronic irreversible form. Interstitial fibrosis is seen in the 
chronic form, The etiology of the chronic form is obscure. Acute and the 
chronic nephrotoxicity Illay have different underlying mechanisms.4 . ~4 
ii. Elec/rolyte imbalance. Potassium retention and magnesium wasting 
arc COllllllon as a result of acute nephrotoxicity. Hyperkalemia may, in the rare 
ca~eI he severe enough to mandate the withdrawal of Cy A for azathioprine. 
Ilypomagnesemia may result in muscle cramps and weakness. paresthesis 
allll even seizures. Magnesium supplementation is often required. 
iii. J/ypertellsioll. Elevated blood pressure can often be attributed to 
Cy A, Increased sympathetic tone with sodium and water retention is the 
likely mechanism; however. concomitant steroid medication may also be the 
cause. High blood pressure caused by CyA frequently appears to be dose 
related and may be secondary to the dose related nephrotoxicity ofthis drug. 
il'. Hirsllfi.llll. Increased hair growth is common. It is most striking on the 
face, but is in fact, generalized. The hair also darkens thus becoming more 
noticeable. This problem is four times as common in young patients as 
opposed to the elderly (more than 55 years old); the incidence being 32% 
versus g(,1. respectively. No correlation with dose has been demonstrated. 
I'. Tremor. A fine tremor is seen in 25% of the patients and is dose related. 
qhi~ tremor is most marked approximately two hours after intake when the 
peak blood level of Cy A is found. 
I'i. Gillgi\'(/iinperpiasia. Gingival hyperplasia is related to oral hygiene. 
It b unusual in bone marrow transplant patients who routinely use antibiotic 
containing toothpaste for decontamination purposes. It is only seen in patients 
who have their own teeth. Improved oral hygiene should be recommended. 
Occasionally gingivectomies are required. 
I'ii. HeplItotoxicity. The incidence of hepatic dysfunction is clearly dose 
related and is seen in less than \0% of patients with the dosages presently 
employed. In renal recipients. bilirubin seems to be the most sensitive 
parameter, but serum measurements of AL T (GPT). AST (GOT), alkaline 
phmphatasc and glutamyltransferase also increase. 35 No c1earcut morphol-
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ogi~ ~hangesK ca~ be se~n on liver biopsy. Accordingly. in liver transplant 
~eclplentsK t~fp dla~nosls m~y b~ very difficult to establish. and the only way 
IS by ~~c1uKsllnK This complication responds readily to dose adjustment. 
VIII: pmu~ ~onge~tjonK Runny or congested nose is often seen with cy-
c1os~onne toxIcity. It IS dose related and responds quickly to dose adjustment. 
IX. Tumors. A high incidence of lymphoproliferative disorders were 
~nit~alKly seen in the CyA trials.12 We now regard tumors in immunosuppressed 
fldlvld~als as a general response to excessive immunosuppression. With 
a~gressl ve dose reduction or total withdrawal of immunosuppression, two-
thuds of these tumors have completely regressed.60 
D. ~y~loKphosphamideK Cyclophosphamide2 is an alkylating agent. Its 
~bsorptlln IS IOcomplete and variable. Cyclophosphamide must be metabo-
lIzed for biologic activity. This normally occurs in the liver microsomes. The 
metabolites are excreted in the urine. Cyclophosphamide is one of the most 
poten~ suppressors ofthe humoral immune system. Its activity on B Iympho-
cytes.ls more pronounced than on T lymphocytes. The initial recommended 
dose IS 2-3 mg/kg/day. but often this must be rapidly reduced due to toxicity 
of the drug. 
. J. Side Effects. i. Leukopenia. Close monitoring of the white cell count 
IS necessary. 
. ii. Alopec~aK a~d cystitis. Alopecia is probably capsed by the compound 
~tselfK The cySt1tls IS caused by the drug metabolites. Both are commonly seen 
10 bone marrow transplants but not with the doses used for solid organ 
transplantation. 
iiiKlnfect~onK Becaus~ ~f its B cell immunosuppressive activity and gen-
eral leukopemc effect. thiS IS a serious concern. 
. E. Ne,,: developments: FKS06, RS61443. The last two years have seen 
an IOcrease 10 the efforts to develop new immunosuppressi ve agents. Two of 
these are presently in clinical evaluation. FK506 (Fujisawa. Osaka. Japan) has 
s~en the longest and the most extensive use, primarily at the University of 
m~usburgh w~ere already well over 1000 patients have recei ved the drug. A II 
kll~s of s?lId or~an recipients. as well as bone marrow transplants and 
patients With autOimmune disorders. have been treated. Randomized mul-
ticenter trials are presently underway in the United States as well as in Europe. 
. .The other ~rugK a mycophenolic acid, which is now commencing its 
clImcal evaluatll~I is RS61443 (Syntex, Palo Alto, California). The experi-
ence of RS61443 In transplantation is very limited at the present time with 
fewer than 20 patients being treated for rescue from rejection. 
Probably the next drug which will shortly enter into Phase I clinical trials 
is oapa~ycin Ety~th~AyerstI Philadelphia, Pennsylvania). This agent, like 
FK506. IS a macrolIde but works through a different pathway. 
92 Immunological Concepts and Immunosuppressionn 
I. FK506. i. Action. The drug is a metabolite produced by Streptomyces 
tsukubaensis. It is a macrolide with a molecular weight of 822 and is 
Iipophilic.·11l. J I.48.61 FK506 inhibits the rnixed lymphocyte reaction a~d ~a~ 
prevent the generation of cytotoxic cells. In fact both FK506 and Cy A mhlblt 
the Ca++ dependent cell activation. This is accomplished through an inhibition 
of IL-2 release and diminution ofIL-2 receptors on activated cytotoxic lym-
phocytes. n 48 
ii. Metabolism. FK506 is rapidly absorbed, and maximum plasma con-
centration is found 1-2 hours after administration. The half-life ranges from 
5.5 to 16.6 hours with a meanof8.7. The plasma clearance ranges from 87 to 
269 Llhour, with a mean of 143 Uhour. The distribution of the drug is 
extensive, volume of distribution of 1342: I, with tissue concentrations in 
decreasing order: lungs. spleen. heart. kidney. pancreas, liver. The bioavaila-
bility isestimated at 25%. The presence of bile is not necessary for absorption. 
However, with deteriorating liver function the bioavailability rapidly in-
creases (21-51 %, mean 36%) and is accompanied by a decreased clearance. 
12.9-70 Llhour. average 39.8 Llhour.28• 70 These changes can result in 
dramatic increases in FK506levels, necessitating resolute dose adjustment. 
FK506 is demethylated and hydroxylated into nine metabolites, some of them 
with weak immunosuppressive properties. 14 Less than I % of a given dose is 
excreted into the urine. and FK506 is not dialyzable.70 
iii. [)rug illteractions. Drug interactions are still mostly uncharted, but 
they appear to be very similar, ifnot identical, to those seen with CyA. CyA 
and FKS06 strongly interact, preventing their metabolism and elimination 
resulting in acute toxic drug levels. Other drugs involving hepatic P450 
metabol ism will arf ect the FK506levels. Barbiturates, antiepileptics and anti-
tuberculars will increase the elimination ofFK506. Ketokonazole, CyA and 
erythromycin will decrease elimination. At this time it is advisable to exert the 
same precautions for potential drug interaction as with CyA. 
il'. Measurement. The available technique for the measurement ofFKS06 
levels is an immunoassay technique. And since the plasmalblood ratio is 
temperature dependent, the plasma has to be separated under temperature 
controlled conditions. The assay also uses overnight incubation.64 In our 
experience. the therapeutic range seems to be 0.4 nglml to 3.0 ng/ml with the 
patients that do well running levels between 0.4 to 0.7 ng/ml. The present 
technique of measuring levels can be expected to undergo much improvement 
and consequently also the recommended FK506 levels. 
1'. Side effects. a. Nephrotoxity. The mechanism for nephrotoxicity is 
probably different from that seen during Cy A treatment since hypertension is 
less common in FK506 treated patients. Hyperkalemia can be a problem with 
both drugs and can be treated effectively with the mineralocorticoid Fluor-
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inef8'. 
Renal function as judged by serum creatinine, BUN and glomerular 
filtration rate seems to be similarly affected by FK506 and CyA at different 
postoperative time points. Early nephrotoxicity posttransplant is seen as a 
sudden drop in urine output accompanied by a rise in BUN, later followed by 
a serum creatinine increase. This toxicity is readily treated with a FKS06 dose 
adjustment, usually in the range of 30-40%. Long term renal dysfunction is 
manageable with fine dose adjustments with an eye to the FK506 level. 
b. Neurotoxity. This is seen in two divergent forms. One is hyperactivity. 
tremulousness, paresthesia, sleeplessness, dreams and/or hallucinations. 
These symptoms can be a litmus test for FK506 dose adjustment. Hyperac-
tivity can be seen even at therapeutic levels. It is easily managed by fine 
decreases in the FK506 dose. 
The other form of neurotoxicity is more serious and normally is seen 
when FK506levels become high, 5 to IO nglml and higher. Patients first 
become hypoactive and then somnolent. This requires sharp and rapid dose 
adjustments without waiting for FK506levels, if daily levels are not avail-
able. The dose should be temporarily stopped or reduced in the order of 80%. 
Further adjustments should be made as soon as a response can be read on 
levels received. This condition is usually seen in patients with cholestasis 
when FK506 pharmacokinetics are altered (see above). 
The neurotoxity profile of FK506 is similar to that of Cy A, and the 
delineation of its subtle aspects was facilitated by years of prior experience 
with the later drug. It is realized now that the binding sites ofthese two drugs 
are part of an ubiquitous network of related small molecular weight protei ns 
whose activation or inactivation affects a wide range of metabolic processes. 
The binding sites are different for the two drugs. but the processes influenced 
are the same. Appreciation of this concept has been a major advance in the 
field of signal transduction apart from the immunologic system and hel ps in 
understanding the related toxic as well as therapeutic profiles ofthis class of 
drugs.48• 56 The immunophilin binding sites are densely represented in the 
central and peripheral nervous system. 
vi. Miscellaneous. Both FKS06 and CyA have a certain diabetogenic 
effect. However, since most patients also receive concomitant steroids this is 
still a side effect that is not fully elucidated. 
Lipid metabolism which is seriously affected by conventional immuno-
suppression is less affected by FK506.1O However unpublished. animal studies 
suggest that cholesterol synthesis in animals is significantly mcreased. The 
lower cholesterol levels seen with FK506 treated patients compared to those 
in the past may reflect the much lower (and often absent) steroid doses that 
are required to prevent rejection. 
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I'ii. Dosing. The presently recommended starting dose when given intra-
vcnously is 0.05 mg/kg every 12 hours as a continuous infusion. The oral 
starting dose is 0.15 mg/kg every 12 hours. Further dose adjustment needs to 
bc done with a view to recorded effects, side effects and reported FK506 
levels. 
I'iii. COl/elusion. FK506 is a very powerful immunosuppressive drug that 
has increased graft and patient survival in liver and heart recipients.68 A 
window has also been opened to new, hitherto "untransplantable" organs. 58 
Fewer and more easily treated rejections are seen in FK506 treated patients 
than in patients receiving CyA. Our knowledge of the drug will rapidly 
increase allowing us to use it more safely and efficiently. Only then can the 
full benefit of this drug be realized. 
IV. Rejection Therapy. 
A. Steroids. With a double drug CyA-steroid maintenance protocol, I 
gram solumedrol methylprednisolone intravenous, followed by an oral 
"recyd ing" of the patient's initial steroids can be used as rejection treatment; 
i.e., 200 mg/day on day I; 160 mg/day on day 2; 120 mg/day on day 3; 80 mg 
per day on day 4; 40 mg/day on day 5; and back to maintenance immunosup-
pression 20 mg per day. For patients on triple drug immunosuppressive 
protocol. (Cy A - azathioprine - steroids), 0.5 gramsolumedrol methylpredni-
solone intravenously for four consecutive days can be used. 
Rt>lIIl'fnber there are as many steroid protocols as there are transplant 
("('I/t('rs! 
n. OK TJ (orthoclone). With the development of monoclonal antibod-
ies directed against the CD3 antigen on T -cells,ls an important step was taken 
toward selecti ve and effecti ve immunosuppression. What developments will 
be seen in future immunosuppressive preparations using monoclonal tech-
ni4ues \) can only be speculative. 
Five mg/day is given intravenously for 10 to 14 days. In the pediatric 
recipient, the daily dose is I mg per day. It is imperative that the patient not 
have any signs of pulmonary congestion before the start of therapy, otherwise 
the risk of acute cardiopulmonary collapse is significantly increased. 
I. Side effects. i. Acute cardiopulmonary collapse. This presents as an an-
aphylactic-like reaction and responds to the same therapy, Le., epinephrine, 
corticosteroids. cardiopulmonary resuscitation. It is only seen after the first, 
or sometimes after the second dose. 
ii. Diarrhea. This is a frequent complaint. Patients should be given 
dietary yogurt in order to recolonize the gastrointestinal tract with nonpatho-
genic lactobacillus. Diphenoxylate hydrochloride (Lomotil) and atropine 
sulphate (Lomotil) and other anticholinergics should be withheld until 
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infectious etiologies for the patient's diarrhea have been excluded. It is very 
commonly seen shortly after injection forthe first few days of therapy . It must 
be differentiated from infection. 
iii. Tingling 0/ hands andfeet. It requires no therapy. 
iv. Headache. This can be severe. It requires symptomatic therapy after 
meningitis has been ruled out. 
v. Meningitis. It is seen as a sterile meningitis. Lumbar puncture may 
show increased cell count. CT of the head is unremarkable, and the develop-
ment of meningitis does not require discontinuation of the drug. 
C. ALGI A TG. The use of antilymphocytic agents such as anti lympho-
cyte globulin/serum (ALG/ ALS) or anti thymocyte globulin (ATG) has been 
plagued by problems such as heterogeneity of the product with batch-to-batch 
variation and unpredictable side effects. Dose differs depending on source 
(horse or rabbit) and manufacturer. Some titrate out the dose attempting to 
keep the T cell count down below 10% of pretreatment levels. Others only 
give a fixed standard dose regimen. 
I. Side effects. Anaphylactic reaction, serum sickness. chills. fever, 
erythema, thrombocytopenia and viral infections, especially cytomega-
lovirus. 
D. Miscellaneous. J. X-ray irradiation. In renal transplantation irradia-
tion has been given for rejection therapy. The usual dose is 150 RAD (deep 
dose) for three days, totaling 450 RAD. The efficaciousness ofthis modality 
has not been established but should not yet be totally discarded.29 
2. Total lymphoid irradiation (TLI). Total lymphoid irradiation is gi ven 
at some centers.54 With this technique, a donor organ needs to be transplanted 
as soon as possible after the completion of the irradiation for the maximum 
benefit. Patients with preformed antibodies are poor candidates for TLI si nee 
finding a crossmatch negative donor may take considerable time. The 
technique can yield good results and is steroid sparing but very cumbersome 
and is not used by us at the present time. 
3. Thoracic duct drainage (TDD). This technique,like TLI, is effective59 
but also unwieldy and thus is falling out of practice. To achieve meaningful 
results, prolonged hospitalization is required. 
V. Organ Specific Recommendations. 
A. Renal transplantation (Table 4). J. Cyclosporine A. The high early 
doses ofCy A which were used have been shown to cause interstitial fibrosis. 32 
Thus today the aim is to avoid the high, early doses to allow the Cy A level to 
build up slowly. No attempt is made to increase a low Cy A level achieved by 
the initial dose during the first week. 
B. Liver transplantation (Tables 5). J. Cyclosporine A. Cy A is started 
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TABLE 4. Renal Transplantation. Triple Drug Immunosuppression 
Regimens. ~~ .s= .s= .s= ~ ~ ----K--K-~--~------------"- C\I C\IC\I COC\l 11> .... .,.... .... 
.... 
Cyclosporine oS tT tT tT tT tT tT 
Preoperative 1M~9po 
Postoperative Sm gq 12hpo 
(2.5 mg/kg q 12h in a nondiuresing pt) Q)G) Q) Q) 
Optimum eyA levels en en 
en CIl 
o 0 0 0 
(12h trough, whole 'C'C 'C 'C II 1ii 1ii blood, monoclonal RIA) ~ ~ Q) < 1 month 150-200 nglml a. (,) ! ! e e 
> 1 month 100-150 nglml :i:i :i :i 
Azathioprine ~~ Cl Cl ..!II: ..!II: 
Preoperative 3 mg/kg po 0,0, 0, 0, E E E E 
Postoperative 2mg/kg po C')C') C') C') 
Adjust according to white cell count ::: Q) Q) Q) Q) 
Cl c: c: c: c: ·c "I: .c: .c: 
..!II: 0.0. a. a. Steroids 0, c: ClOO ~~~ ClClO E 0 ..!II:'- .- ~~£ See Table 3 ~ o,.s=.s= (5 C') N ~b!! E E m E E :s () 0 Q) ~ ilo~ Transfusions .9 00-_ LO 0 __ a. c: Q"'=oo ~IKKK;o Kw-=~o 
No protocol preoperative transfusions are given. Transfusions only given e Cl-· K~ :::J 0- () 
..!II:oCo en 
when indicated medically. Leukocyte poor (washed) PRBCs are preferred. Q) 0,3' .- as 
c: E ~ > .;:: Q) 
8. OON 
... 
.... Z« ~ en 0 U ... 
>- Q) () ~ 
according to pre- and intraoperative renal function and by the function of the Q) 
as 
> ~ 
liver graft a~ assessed intraoperatively. ~ :::J c:: 0 c:: 
Postoperatively, as long as renal function is poor, noCy A is given. A low 
Q) ~ .s= .S! a. ~ 13 0 () 
dose i~ given only after brisk diuresis, >\OOmllhr, has been seen for a l!! c:: .,.... c:: 
C ~ 'C ~ Iii a; Iii 
minimum of 12 hours. The CyA dose is then adjusted to achieve a CyA level - Q) iii as ... iii c: c: c: ( 12 hour trough, whole blood, monoclonal RIA) of: 'C E 'iii "UD~ ... UD~D" "CK~ .... c: c:: "'0. c:: as 0 o as 0 as Q) o E CD o as&. 
, a: z_ a: ClE ClE8. g,E8. 
! 
< I month 250-400 ng/ml 0-
1-3 months 200-300 nglml c 0 
> 3 months 180-250 ng/ml ~ 
C 
as :; 
Iligh Cy A levels are initially required to achieve adequate immunosup- c. CIl a. 
pression because of the preservation damaged liver's inability to excrete CyA 
c: ~ -:; ~ ~ (; 0 and its metabolites. OncetheGI tract has begun to function, oral CyA is added I- j:: U~ E Qj j:: ~ c:: >-.0 :::J to the same intravenous regimen at 15 mglkg every 12 hours. To ensure that ... i 'C > ~ .S! .0 'C &. 0 ~ IJ.J u'Cc: E 0 adequate Cy A levels are maintained on oral therapy, the intravenous dose is Iri ~ ~ c:: Q) as Cl 
slowly tapered over 7 -10 days following daily levels. The oral Cy A dose may UJ @ "( ~Kg>lw ....J e: .... :::J Q) CD II) K~ c: 
c( ~ =-rl~ ~ '- as 0 I- -K/~C/l 
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h~ as high as 25 mg/kg every 12 hours until the biliaryT-tube isclamped (one 
week after transplantation). When this is done a rapid downward dose 
adjustlllent is usually needed to curb soaring Cy A levels. When the Cy A level 
increases to more than 600 ng/mlthe next (usually evening) dose is withheld 
and then a reduced, 2()li(, dose is started 24 hours after the last given dose 
(usually next morning). It is important to remember that the blood level 
Illea.smed the following day is a 24-hour trough, not a 12-hour trough and 
accordingly will be lower than one might have anticipated for a 12-hour 
trough. Failure E~r the [n'el to decrease after withholding a dose is an 
illdiclI/ioll ora 1lE}/~filtlED/iE}llillg liver graft! 
2. k;athioprille jilT rellal prophylaxis. In general preoperative azathi-
oprine is given only to patients with impaired renal function. In an uric/ 
oliguric patients a :\ mg/kg dose is given preoperatively and maintained 
postoperatively, as allowed by the patient's white blood cell count, until the 
rellal function is reestablished. Azathioprine is then discontinued. 
3. A;:.atlriol'rille./cJI· rejectioll. Azathioprine is started at 1.0 mg/kg/day 
after treatment of a first episode of rejection and is maintained indefinitely at 
0.5-1.0 mg/kg/day if this is tolerated by the patient. 
.J. Steroids. Sec Table 2. 
C. Heart and heartllung transplantation. 1. Cyclosporine A. It is 
prese nt I y lInc lear why heart transplant recipients appear to be more sensitive 
to the nephrotox it: effects ofCy A. This has mandated the use of very low Cy A 
doses heginning early after heart transplantation. One reason may be that the 
native kidneys of heart transplant recipients are more sensitive to vasospasm 
and Ihus 10 Cy A nephrolox icity than the denervated transplanted kidney .It is 
not dear how then 10 explain the disparity between heart and liver recipients 
in this regard. However, because of the fear of rejection, there is a tendency 
to u:-.e high Cy A long term maintenance levels in heart transplantation. 
( 'yc/o.ll'orille. 
Preoperative: 
Postoperative: 
A ;:'{Itiziuprille. 
Preoperative: 
Postoperat i ve: 
RATG. 
Postopcrat ive: 
() 
2.5-5 mg/kg every 12 hours and adjust to maintain a CyA 
level (12-hour trough, whole blood, monoclonal RIA) of 
250-40() ng/ml. Long term 200-300 ng/m\. 
4 mg/kg 
2 Illg/kg/day for 5 days, then discontinue. 
100 Il1g/day for 5 days. 
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Steroids. See Table 2. ' I 
D. ~ancreas transplantation. I. Cyclosporine A. In the combined trans-
pl~nt~l1on of ~ancr~as and renal allografts. the kidney serves as a marker for 
rejeclton. USlOg thIS combined method, high success rates have been re-
ported.69 q~ assure that CyA nephrotoxicity mimicking rejection is not 
confused With true allograft rejection, low CyA dosages and levels are 
employed. 
Cyclosporine. 
Preoperative: o 
Postoperati ve: 3 mg IV over 24 hours. 5 mglkg q 12 hours starting postop 
day 7. Adjust according to blood levels. 
Azathioprine. 
Preoperative: 2 mglkg IV 
Postoperative: 2 mg/kg/day for I week, then lowered to I mglkg/day. 
OKTJ . 
Preoperative: 5 mglkg IV 
Postoperative: 5 mg/kg IV for I week then discontinue. 
Sleroids. See renal protocol. 
I. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
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V. Glossary of Terms 
in the Human Transplant Directed Immune Response 
Acute Rejection. Destruction of a transplant by i!JllIlunological reactions, 
usually seen five days to two months after grafting. ("Accelerated acute 
rejection" takes place one to five days postop usually as a result of a pre-
existing cellular immune reactivity.) 
ADCC. Antibody dependent cell mediated cytotoxicity (see K cells). 
Adjuvant. Substance that enhances an immune response when admini-
stered together with an antigen. 
Agammaglobulinemia. Congenital deficiency of gamma globulins (he-
reditary or sporadic). 
Agglutination. Aggregation of large particles, i.e., red blood cells as a 
result of antigen-antibody reactions on the surface of the particles. 
Allotransplantation (allografting). Transplantation between different 
individuals of the same species. 
Anaphylaxis. Rapid hypersensitivity response of "immediate type" 
occurring within minutes after the administration o(the challenging antigen. 
, ! 
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Antibody. Complex protein molecule that combines with antig~ns in a 
"lock and key" fashion (as a first step to initiate a sequence of reactfl~sFK 
Antigen. Molecule(s) that can evoke an immune response whe~ l~tro­
duced into an individual or when exposed to immunocom~etenKt cells m vftr~K 
Antilymphocyte Globulin (ALG) or Se rum (A.LS). AntIbodIes (serum) di-
rected to lymphoid cell antigens in another speCies: . 
Arthus Reaction. Hemorrhagic necrotic skin lesIOn developmg a~ a.result 
of a reaction between circulating precipitating antibodies and locally Injected 
antigens. . ... . ., 
Autoantibody. Antibody with specIfICIty dIrected agaInst antigenIc 
structures in the individual producing the antibody ("self" antigens).. . 
Autoimmune Disease. A disease causing, resulting from, or appeanng SI-
multaneously with an inunune reaction to "self' antig~nsK . . 
Autotransplantation (autografting). TransplantatIOn of an organ InSIde 
the same individual. . 
B cell (B lymphocyte). "Bursa" equivalent or bone marrow denved lym-
phocyte concerned with antibody mediated immunity. . . 
Bradykinin. A peptide that can increase vascular permeabIlIty, lower 
blood pressure and contract smooth muscle. The effects are enhanced by 
prostaglandins. . .. 
Bursa Fabricius. Organ in birds where the dIfferentiation of stem cells 
into B cells takes place. 
Cell Mediated Immune Reactions. Expression of immune responses that 
involve interactions between sensitized cells and antigens. .. 
Cell Mediated Lympholysis (CML). In vitro model of allog~aft rejectIOn 
with killing of target cells by lymphocytes. At the present tIme, more a 
research tool than a clinical tool. . . 
Chemotaxis. Unidirectional movement by a cell towards an mcreasmg 
gradient of an attractant. . . 
Chime ra. Person or animal with populatIOns of lymphOid cells from two 
individuals. Tolerance exists between the two populations. . 
Chronic Rejection. Destruction of a transplant by immunologIcal reac-
tions usually seen months to years after grafting. .. 
Class I and II Antigens. Groups of human transplant (major hIstocom-
patibility complex) antigens initiating different kinds of immun~ response.s. 
Complement. A group of at least 20 proteins ~hat circulate m plasma m 
inactive forms. When an antigen/antibody reactIOn has taken place, they 
become sequentially activated in order for destruction of the target structures 
to take place. . .. 
Coombs Reaction. "The antiglobulin reaction". The creatIOn ofbndgmg 
between two antibody coated red cells by the addition of antibodies to the 
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coating antibodies. A resulting cell agglutination is recorded cither "directly" 
or "indirectly". In the former case, red cells are already coated wi th anti bodies 
and in the latter, circulating antibodies, if any, are allowed to adhere to the red 
cells before the test is carried out. 
Crossmatch Test. The detection of preformed donor directed cytotoxic 
antibodies in a patient awaiting organ transplantation. Donor target (lym-
phoid) cells, recipient serum and complement are brought together. 
Cryoglobulin. Immunoglobulin that is insoluble at below body tempera-
tures. 
Delayed Hypersensitivity. Manifestation of cell mediated immune reac-
tions. 
Dendritic Cell. Interstitial cell with an important role of presenting 
foreign antigens to the host after transplantation. Someti mes called "pas<;en-
ger leukocyte". 
Enhancement. Complex phenomenon where the survival of a graft or 
tumor is facilitated by the presence of noncytotoxic antibodies with speci fic-
ity against graft or tumor antigens. 
E Rosettes. See Rosettes 
Fahl Fe Fragments. Parts of immunoglobulin molecules resulting from 
cleavage of polypeptide chains and breaking of disulfide bonds. 
Gammaglobulin. Immunoglobulin. 
Graft- Versus-Host (GVH) Reaction. An immune response to host anti-
gens created by immunocompetent cells from the organ donor. 
Granulocytes. Neutrophil, eosinophil and basophil lymphocytes. The 
former two are phagocytes. 
Hapten. A low molecular weight substance that is only immunogenic 
(antigenic) when coupled to a larger carrier molecule. 
Helper Cell. Subclass of T cells interacting with precursors of the 
cytotoxic T cells and plasma cells allowing them to mature. Also called 
"helper and inducer cell". 
Heterologous Transplantation. Older nomenclature, translates into 
"xenografting". 
HIA Matching. The selection of human donor-recipient pairs with 
minimal antigenic differences in organ transplantation, HLA= human leu-
cocyte antigens. 
Homologous Transplantation. Older nomenclature. translates into allo-
grafting. 
Humoral Immune Response. Antibody mediated immune response. 
Hyperacute Rejection. The destruction of a vascularized transplant 
within minutes to a few hours after the establishment of blood flow through 
the organ. Preformed cytotoxic antibodies are instrumental in the process. 
--_._---_ .. __ .... _ .. _------
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Idiotype. A determinant present on antibodies that appears to represent 
the antigenicity of the antigen binding site itself. 
Immediate-type Immune Response. Antibody mediated immune re-
~pEFnseK 
Immlllle ClIlIlplex Disease. "Serum sickness", A generalized disease 
developing secondary to the formation of circulating antigen-antibody com· 
plexes. Vascular. renal. joint and cutaneous lesions occur. 
Im/ll 1/1 109 !obll lill. Gammaglobulin. 
Immlllwde/ki('llcy Diseases. Clinical sequelae of impaired function in 
one or more components of the immune system. 
1IIlIIlllllomolilllatioll (Immunopotent;ation or Immunosuppression). 
Regulation of immune responses. Immunopotentiation---"up" regulation. 
I mmunosuppression---"down" regulation 
Illcillcer Cel/. See "helper" cell. 
Illter/iToll. Proteins produced orreleased by cells following viral infec-
tion or after exposure to "inducers". Interferons are mainly antiviral (alpha 
and beta) or mainly immunoregulatory (gamma). 
K Cell. Lymphoid cell of importance in antibody dependant cell medi-
ated cytotoxicity (ADCC). Cytotoxic activity directed toward target cells 
coated with specific antibodies. 
Killer Cell. Lymphoid cell able to lyse target cells. End product of the 'T 
cell re~ponse" to an antigenic challenge. 
Lellcot rienes.Metabolites of arachidonic acid with functions associated 
with chemotactic activity and smooth muscle contractility. 
L."mpi!ocYte. Cell belonging to a family of cells with immune response 
functions. Can be classified on morphological or functional grounds. 
LympllOkilles. Effector molecules released from lymphoid cells when re-
acting with specific antigens in vitro. 
Macrophage. Phagocytic cell with a role in antigen recognition and 
processing. 
Maior Histocompatibility Complex (MHC). Chromosomal region con-
~isting of a series of genes that code for the cell surface expression of strong 
transplantation antigens (HLA). 
Mast cells. Cells with a reservoir function forvasoactive amines particu-
larly histamine. 
Memory Cell. Cells formed following antigenic stimulation of either B 
or T lymphoid cells that proliferate and differentiate upon reencounter with 
the antigen in question. 
Microglohlllil! EB~ J. 11600 Dalton cell surface protein associated with the 
Class I HLA system. 
Migratioll Inhibitioll.The failure of macrophages to migrate from a 
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capillary tube when the antigen to which the macrophage donor is sensitized 
is present in the incubation medium. MIF - "migration inhibitory factor". 
Minor Antigens. Non-MHC antigens with unclear role in transplantation. 
Mixed Lymphocyte Culture Reaction (MLC or MLR). The mitotic reac-
tion within a lymphocyte population when it is mixed with a foreign 
population of lymphoid cells. 
Monitoring. Assessment of host immune response capacity. 
Monoclonal Antibodies. Antibodies manufactured by cells derived from 
one B cell producing antibodies with one specificity. 
Monocyte. Mononuclear phagocyte with multiple functions in the im-
mune response. Can differentiate into tissue macrophages after leaving the 
bloodstream. 
Natural Killer (NK) Cell. Cell with no known T or B cell marker that is 
involved in nonspecific killing of cells with foreign surface markers, i.e .. 
allograft cells, virally transformed cells, tumor cells. 
Null Cell. Small population ofthe lymphocyte pool in a given individual 
that lacks the antigenic characteristics ofT or B cells. Null cells can be di vided 
into NK cells and K cells. 
OKT Series. Set of mouse antihuman monoclonal antibodies directed 
against different T cell surface markers. 
Opsonization. Facilitation of phagocytosis by the presence of antigens 
coated with antibodies. 
Passenger Leukocyte. See Dendritic cell. 
Phagocytosis. Ingestion of particles into cells. UsualIy represents the 
initial host encounter with a foreign substance. 
Plasma Cell. CelI producing and secreting immunoglobulins. End prod, 
uct of the "B cell response" to an antigenic challenge. 
Thromboxolle. Metabolite of arachidonic acid causing smooth muscle 
constriction and platelet aggregation. 
Tissue Typing. Determination ofthe major histocompatibility complex 
(MHC) code for a given individual (in preparation for the selection of 
matched donor/recipient pairs). 
Tolerance. A state of immune nonresponsiveness to specific antigen(sJ 
normally capable of inducing immune reactivity. 
Total Body Irradiation. Total Lymphoid Irradiation (TLI). The irradia-
tion of an entire transplant recipient or areas of the body housing lymphoid 
tissues. Administered to achieve immunosuppression in preparation for 
organ transplantation or infusion of cellular antigens. 
Transfer Factor. Substance released following the in vitro interaction be-
tween a sensitized lymphocyte and its specific antigen. It has the capacity to 
transfer the cellular immune reactivity to a nonreactive individual. 
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XenotrallSplantation (Xenografting). Transplantation between individu-
als belonging to different species. 
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CHAPTER FOUR 4 
Anesthesia for Organ 
Transplantation 
Yoogoo Kang 
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Joseph A. Wels 
This chapter is dedicated to Dr. Char/es W Schertz, our beloved 
friend and an inspiring anesthesiologist, who passed away during his 
third Mt. Everest expedition. 
I. Heart Transplantatlol1 
II. HeartlLung Transplantation 
III. Lung Transplantation 
IV. Liver Transplantation 
V. Pediatric Liver Transplantation 
VI. Kidney Transplantation 
VII. Pancreas Transplantation 
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